Baylor College of Medicine

Duke University

Spencer, David

Slawin, Kevin

Hanks, Brent

Brent Hanks

David Spencer

Kevin Slawin

Fei Zhao

Balamayooran Theivanthiran

Nicholas Devito

Kevin M Slawin

The present disclosure provides, in part, compositions and methods of increasing the efficacy of anti-PD-1/PD-L1 antibody immunotherapy in a subject. The compositions and methods comprise an NLRP3 inhibitor used in combination with a PD-1 or PD-L1 inhibitor for the treatment of cancer.

Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies

The present disclosure provides methods of detecting a wnt-&#x3b2;-catenin-mediated cancer and an immunotherapy resistant cancer by detecting the presence of an associated biomarker. Further, methods of threating the wnt-&#x3b2;-catenin-mediated cancer or immunotherapy resistant cancer are provided.

Predictive biomarkers for cancer immunotherapy and methods of using same

This disclosure provides compositions of matter and methods for alteration of dendritic cell metabolism to augment cancer vaccine efficacy. The compositions and methods can involve regulation of fatty acid oxidation.

Composition of matter and methods for alteration of dendritic cell metabolism to augment cancer vaccine efficacy

The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.

Induced activation in dendritic cells

Induced activation in dendritic cell

Growing community of inventors

Houston, TX, United States of America

Brent Hanks